Spots Global Cancer Trial Database for Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC
Official Title: An Open-label, Randomized, Phase II Clinical Trial Comparing the Efficacy and Safety of Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for Metastatic Colorectal Cancer
Study ID: NCT03792269
Study Description
Brief Summary: XELOX as first-line treatment regimen has limited efficacy against patients with metastatic colorectal cancer (mCRC). Peritoneal metastasis is one of the most lethal factor for mCRC. Intraperitoneal chemotherapy has became a widely accepted strategy in the treatment of peritoneal dissemination. We hypothesized that combined multi-channel administration, such as intraperitoneal chemotherapy, oral chemotherapy, and intravenous chemotherapy, can produce better results than XELOX for first-line treatment for mCRC patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
Contact Details
Name: Jing Jing
Affiliation: The Comprehensive Cancer Center of Nanjing Drum Tower Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
